{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:22:56Z","timestamp":1793035376031,"version":"4.5.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:00:00Z","timestamp":1644278400000},"content-version":"am","delay-in-days":403,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006513","name":"Duke Clinical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1 R01 HL146158-01"],"award-info":[{"award-number":["1 R01 HL146158-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL132448"],"award-info":[{"award-number":["R01 HL132448"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 HL087366"],"award-info":[{"award-number":["UM1 HL087366"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006510","name":"Duke University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005292","name":"Brigham and Women's Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005292","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1U01HL148690-01"],"award-info":[{"award-number":["1U01HL148690-01"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["5T32HL007936-15"],"award-info":[{"award-number":["5T32HL007936-15"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.carrev.2020.06.031","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T19:51:49Z","timestamp":1593546709000},"page":"100-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Clinical Safety Profile of Transendocardial Catheter Injection Systems: A Plea for Uniform Reporting"],"prefix":"10.1016","volume":"22","author":[{"given":"Amish N.","family":"Raval","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl J.","family":"Pepine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.carrev.2020.06.031_bb0005","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/trf.12826","article-title":"Cell-based therapies for cardiac disease: a cellular therapist\u2019s perspective","volume":"55","author":"Young","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.carrev.2020.06.031_bb0010","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00129784-200808050-00004","article-title":"Therapeutic potential of adult progenitor cells in the management of chronic myocardial ischemia","volume":"8","author":"Raval","year":"2008","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.carrev.2020.06.031_bb0015","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1161\/CIRCULATIONAHA.112.000230","article-title":"Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy","volume":"128","author":"Vrtovec","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2020.06.031_bb0020","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.yjmcc.2007.09.012","article-title":"Comparison of intracoronary and transendocardial delivery of allogeneic mesenchymal cells in a canine model of acute myocardial infarction","volume":"44","author":"Perin","year":"2008","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"10.1016\/j.carrev.2020.06.031_bb0025","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ahj.2007.04.051","article-title":"Transendocardial autologous bone marrow in chronic myocardial infarction using a helical needle catheter: 1-year follow-up in an open-label, nonrandomized, single-center pilot study (the TABMMI study)","volume":"154","author":"de la Fuente","year":"2007","journal-title":"American Heart Journal"},{"key":"10.1016\/j.carrev.2020.06.031_bb0030","first-page":"447","article-title":"Evaluation of the acute and chronic safety of the biosense injection catheter system in porcine hearts","volume":"48","author":"Kornowski","year":"1999","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2020.06.031_bb0035","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1583\/04-1386R.1","article-title":"Transcatheter transplantation of autologous skeletal myoblasts in postinfarction patients with severe left ventricular dysfunction","volume":"11","author":"Ince","year":"2004","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.carrev.2020.06.031_bb0040","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1161\/CIRCINTERVENTIONS.112.000422","article-title":"Optimized delivery system achieves enhanced endomyocardial stem cell retention","volume":"6","author":"Behfar","year":"2013","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2020.06.031_bb0045","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1161\/01.CIR.95.6.1611","article-title":"A novel method for nonfluoroscopic catheter-based electroanatomical mapping of the heart. In vitro and in vivo accuracy results","volume":"95","author":"Gepstein","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2020.06.031_bb0050","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1038\/nm1296-1393","article-title":"Nonfluoroscopic, in vivo navigation and mapping technology","volume":"2","author":"Ben-Haim","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.carrev.2020.06.031_bb0055","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12265-009-9138-1","article-title":"Intramyocardial navigation and mapping for stem cell delivery","volume":"3","author":"Psaltis","year":"2010","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.carrev.2020.06.031_bb0060","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1161\/CIRCRESAHA.111.245993","article-title":"Intramyocardial, autologous CD34+ cell therapy for refractory angina","volume":"109","author":"Losordo","year":"2011","journal-title":"Circ Res"},{"key":"10.1016\/j.carrev.2020.06.031_bb0065","doi-asserted-by":"crossref","first-page":"732","DOI":"10.4244\/EIJV8I6A113","article-title":"Percutaneous, transendocardial injection of bone marrow-derived mononuclear cells in heart failure patients following acute ST-elevation myocardial infarction: ALSTER-stem cell trial","volume":"8","author":"Heeger","year":"2012","journal-title":"EuroIntervention"},{"key":"10.1016\/j.carrev.2020.06.031_bb0070","first-page":"169","article-title":"The Athena trials: autologous adipose-derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunction","volume":"89","author":"Henry","year":"2017","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2020.06.031_bb0075","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ahj.2005.04.033","article-title":"Direct intramyocardial percutaneous delivery of autologous bone marrow in patients with refractory myocardial angina","volume":"151","author":"Briguori","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.carrev.2020.06.031_bb0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jcin.2008.11.003","article-title":"One-year follow-up of feasibility and safety of the first U.S., randomized, controlled study using 3-dimensional guided catheter-based delivery of autologous skeletal myoblasts for ischemic cardiomyopathy (CAuSMIC study)","volume":"2","author":"Dib","year":"2009","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2020.06.031_bb0085","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.jacc.2013.02.071","article-title":"Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics","volume":"61","author":"Bartunek","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2020.06.031_bb0090","first-page":"648","article-title":"Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial","volume":"38","author":"Bartunek","year":"2017","journal-title":"European Heart Journal"},{"key":"10.1016\/j.carrev.2020.06.031_bb0095","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12967-016-0918-5","article-title":"Effects of the intramyocardial implantation of stromal vascular fraction in patients with chronic ischemic cardiomyopathy","volume":"14","author":"Comella","year":"2016","journal-title":"J Transl Med"},{"key":"10.1016\/j.carrev.2020.06.031_bb0100","doi-asserted-by":"crossref","first-page":"805","DOI":"10.4244\/EIJV6I7A139","article-title":"Final results of a phase IIa, randomised, open-label trial to evaluate the percutaneous intramyocardial transplantation of autologous skeletal myoblasts in congestive heart failure patients: the SEISMIC trial","volume":"6","author":"Duckers","year":"2011","journal-title":"EuroIntervention"},{"key":"10.1016\/j.carrev.2020.06.031_bb0105","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s12265-014-9580-6","article-title":"Endomyocardial implantation of autologous bone marrow mononuclear cells in advanced ischemic heart failure: a randomized placebo-controlled trial (END-HF)","volume":"7","author":"Santoso","year":"2014","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.carrev.2020.06.031_bb0110","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2012.418","article-title":"Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial","volume":"307","author":"Perin","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.carrev.2020.06.031_bb0115","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.amjcard.2005.09.132","article-title":"Safety and feasibility of transendocardial autologous bone marrow cell transplantation in patients with advanced heart disease","volume":"97","author":"Fuchs","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.carrev.2020.06.031_bb0120","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/ejhf.700","article-title":"Safety, feasibility and effectiveness of first in-human administration of muscle-derived stem\/progenitor cells modified with connexin-43 gene for treatment of advanced chronic heart failure","volume":"19","author":"Gwizdala","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.carrev.2020.06.031_bb0125","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1161\/CIRCRESAHA.115.304554","article-title":"Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy","volume":"115","author":"Henry","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.carrev.2020.06.031_bb0130","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/S0140-6736(16)30137-4","article-title":"Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial","volume":"387","author":"Patel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2020.06.031_bb0135","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/hrt.2008.155077","article-title":"Percutaneous intramyocardial stem cell injection in patients with acute myocardial infarction: first-in-man study","volume":"95","author":"Krause","year":"2009","journal-title":"Heart"},{"key":"10.1016\/j.carrev.2020.06.031_bb0140","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.106.687376","article-title":"Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I\/IIa double-blind, randomized controlled trial","volume":"115","author":"Losordo","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2020.06.031_bb0145","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ijcard.2016.02.016","article-title":"Intramyocardial transplantation of mesenchymal stromal cells for chronic myocardial ischemia and impaired left ventricular function: results of the MESAMI 1 pilot trial","volume":"209","author":"Guijarro","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.carrev.2020.06.031_bb0150","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/ncpcardio1388","article-title":"Combined delivery approach of bone marrow mononuclear stem cells early and late after myocardial infarction: the MYSTAR prospective, randomized study","volume":"6","author":"Gyongyosi","year":"2009","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.carrev.2020.06.031_bb0155","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1161\/01.CIR.0000070596.30552.8B","article-title":"Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure","volume":"107","author":"Perin","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2020.06.031_bb0160","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1161\/CIRCRESAHA.115.306332","article-title":"A phase II dose-escalation study of allogeneic mesenchymal precursor cells in patients with ischemic or nonischemic heart failure","volume":"117","author":"Perin","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.carrev.2020.06.031_bb0165","doi-asserted-by":"crossref","unstructured":"Perin EC, Silva GV, Zheng Y, Gahremanpour A, Canales J, Patel D, Fernandes MR, Keller LH, Quan X, Coulter SA, Moore WH, Herlihy JP and Willerson JT. Randomized, double-blind pilot study of transendocardial injection of autologous aldehyde dehydrogenase-bright stem cells in patients with ischemic heart failure. Am Heart J. 2012;163:415\u201321, 421 e1.","DOI":"10.1016\/j.ahj.2011.11.020"},{"key":"10.1016\/j.carrev.2020.06.031_bb0170","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2012.25321","article-title":"Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial","volume":"308","author":"Hare","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.carrev.2020.06.031_bb0175","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jacc.2016.11.009","article-title":"Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM Trial","volume":"69","author":"Hare","year":"2017","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.carrev.2020.06.031_bb0180","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ahj.2011.07.020","article-title":"A double-blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction","volume":"162","author":"Povsic","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.carrev.2020.06.031_bb0185","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1093\/eurheartj\/ehm485","article-title":"Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial)","volume":"28","author":"Tse","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2020.06.031_bb0190","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1161\/CIRCRESAHA.116.309009","article-title":"Effects of transendocardial delivery of bone marrow-derived CD133(+) cells on left ventricle perfusion and function in patients with refractory angina: final results of randomized, double-blinded, placebo-controlled REGENT-VSEL trial","volume":"120","author":"Wojakowski","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.carrev.2020.06.031_bb0195","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/j.jacc.2003.06.017","article-title":"Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up","volume":"42","author":"Smits","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2020.06.031_bb0200","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/jama.2013.282909","article-title":"Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial","volume":"311","author":"Heldman","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.carrev.2020.06.031_bb0205","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1161\/CIRCRESAHA.117.311827","article-title":"Dose comparison study of allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy (The TRIDENT Study)","volume":"121","author":"Florea","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.carrev.2020.06.031_bb0210","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0140-6736(03)12111-3","article-title":"Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation","volume":"361","author":"Tse","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2020.06.031_bb0215","doi-asserted-by":"crossref","first-page":"632","DOI":"10.5966\/sctm.2015-0172","article-title":"Efficacy of CD34+ stem cell therapy in nonischemic dilated cardiomyopathy is absent in patients with diabetes but preserved in patients with insulin resistance","volume":"5","author":"Vrtovec","year":"2016","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.carrev.2020.06.031_bb0220","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1161\/CIRCRESAHA.117.312170","article-title":"Effects of repetitive transendocardial CD34(+) cell transplantation in patients with nonischemic dilated cardiomyopathy","volume":"123","author":"Vrtovec","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.carrev.2020.06.031_bb0225","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1161\/CIRCRESAHA.111.242610","article-title":"Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling","volume":"108","author":"Williams","year":"2011","journal-title":"Circ Res"},{"key":"10.1016\/j.carrev.2020.06.031_bb0230","first-page":"372","article-title":"A randomized, double-blind, placebo-controlled, multicenter, pilot study of the safety and feasibility of catheter-based intramyocardial injection of AdVEGF121 in patients with refractory advanced coronary artery disease","volume":"68","author":"Fuchs","year":"2006","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2020.06.031_bb0235","first-page":"899","article-title":"High-dose plasmid-mediated VEGF gene transfer is safe in patients with severe ischemic heart disease (Genesis-I). A phase I, open-label, two-year follow-up trial","volume":"82","author":"Favaloro","year":"2013","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2020.06.031_bb0240","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/eurheartj\/ehn233","article-title":"Release of biomarkers of myocardial damage after direct intramyocardial injection of genes and stem cells via the percutaneous transluminal route","volume":"29","author":"Baldazzi","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2020.06.031_bb0245","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1161\/01.CIR.0000015982.70785.B7","article-title":"Phase 1\/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia","volume":"105","author":"Losordo","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2020.06.031_bb0250","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/mt.2009.70","article-title":"VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial","volume":"17","author":"Stewart","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.carrev.2020.06.031_bb0255","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1161\/CIRCRESAHA.111.300440","article-title":"An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure","volume":"112","author":"Penn","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.carrev.2020.06.031_bb0260","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1093\/eurheartj\/ehl117","article-title":"Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease","volume":"27","author":"Ripa","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2020.06.031_bb0265","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1093\/eurheartj\/ehv254","article-title":"Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized phase II trial","volume":"36","author":"Chung","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2020.06.031_bb0270","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ahj.2010.11.023","article-title":"Intramyocardial plasmid-encoding human vascular endothelial growth factor A165\/basic fibroblast growth factor therapy using percutaneous transcatheter approach in patients with refractory coronary artery disease (VIF-CAD)","volume":"161","author":"Kukula","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.carrev.2020.06.031_bb0275","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s13287-018-0969-z","article-title":"Linking cell function with perfusion: insights from the transcatheter delivery of bone marrow-derived CD133(+) cells in ischemic refractory cardiomyopathy trial (RECARDIO)","volume":"9","author":"Bassetti","year":"2018","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.carrev.2020.06.031_bb0280","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1161\/CIRCRESAHA.115.303463","article-title":"Selected CD133(+) progenitor cells to promote angiogenesis in patients with refractory angina: final results of the PROGENITOR randomized trial","volume":"115","author":"Jimenez-Quevedo","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.carrev.2020.06.031_bb0285","first-page":"214","article-title":"Catheter-based transendocardial delivery of autologous bone-marrow-derived mononuclear cells in patients listed for heart transplantation","volume":"31","author":"Silva","year":"2004","journal-title":"Tex Heart Inst J"},{"key":"10.1016\/j.carrev.2020.06.031_bb0290","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ahj.2014.03.022","article-title":"Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: the PRECISE trial","volume":"168","author":"Perin","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.carrev.2020.06.031_bb0295","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jacc.2004.12.068","article-title":"Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris a randomized double-blind placebo-controlled study: the Euroinject one trial","volume":"45","author":"Kastrup","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl. 1","key":"10.1016\/j.carrev.2020.06.031_bb0300","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1038\/ncpcardio0447","article-title":"Methods of stem cell delivery in cardiac diseases","volume":"3","author":"Perin","year":"2006","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.carrev.2020.06.031_bb0305","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1536\/ihj.16-179","article-title":"Improvement of local cell delivery using helix transendocardial delivery catheter in a porcine heart","volume":"58","author":"Mitsutake","year":"2017","journal-title":"Int Heart J"},{"key":"10.1016\/j.carrev.2020.06.031_bb0310","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1161\/01.CIR.0000095790.28368.F9","article-title":"Magnetic resonance fluoroscopy allows targeted delivery of mesenchymal stem cells to infarct borders in swine","volume":"108","author":"Dick","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2020.06.031_bb0315","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/hrt.2004.034363","article-title":"Real time magnetic resonance guided endomyocardial local delivery","volume":"91","author":"Corti","year":"2005","journal-title":"Heart"},{"key":"10.1016\/j.carrev.2020.06.031_bb0320","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/mrm.20086","article-title":"MR-trackable intramyocardial injection catheter","volume":"51","author":"Karmarkar","year":"2004","journal-title":"Magn Reson Med"},{"key":"10.1016\/j.carrev.2020.06.031_bb0325","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.compmedimag.2013.03.006","article-title":"MRI-3D ultrasound-X-ray image fusion with electromagnetic tracking for transendocardial therapeutic injections: in-vitro validation and in-vivo feasibility","volume":"37","author":"Hatt","year":"2013","journal-title":"Comput Med Imaging Graph"},{"key":"10.1016\/j.carrev.2020.06.031_bb0330","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s12265-015-9654-0","article-title":"Intravenous followed by X-ray fused with MRI-guided transendocardial mesenchymal stem cell injection improves contractility reserve in a swine model of myocardial infarction","volume":"8","author":"Schmuck","year":"2015","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.carrev.2020.06.031_bb0335","first-page":"468","article-title":"Targeted transendocardial therapeutic delivery guided by MRI-x-ray image fusion","volume":"78","author":"Tomkowiak","year":"2011","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2020.06.031_bb0340","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1161\/CIRCULATIONAHA.105.598524","article-title":"X-ray fused with magnetic resonance imaging (XFM) to target endomyocardial injections: validation in a swine model of myocardial infarction","volume":"114","author":"de Silva","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2020.06.031_bb0345","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1002\/mp.12913","article-title":"A dynamic model-based approach to motion and deformation tracking of prosthetic valves from biplane x-ray images","volume":"45","author":"Wagner","year":"2018","journal-title":"Med Phys"},{"key":"10.1016\/j.carrev.2020.06.031_bb0350","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1118\/1.4941950","article-title":"4D interventional device reconstruction from biplane fluoroscopy","volume":"43","author":"Wagner","year":"2016","journal-title":"Med Phys"},{"key":"10.1016\/j.carrev.2020.06.031_bb0355","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ahj.2012.06.022","article-title":"Incidence and clinical significance of cardiac biomarker elevation during stem cell mobilization, apheresis, and intramyocardial delivery: an analysis from ACT34-CMI","volume":"164","author":"Povsic","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.carrev.2020.06.031_bb0360","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jacc.2010.12.005","article-title":"Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the valve academic research consortium","volume":"57","author":"Leon","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2020.06.031_bb0365","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2020.06.031_bb0370","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1161\/CIRCRESAHA.119.314951","article-title":"Phase 3 DREAM-HF trial of mesenchymal precursor cells in chronic heart failure","volume":"125","author":"Borow","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.carrev.2020.06.031_bb0375","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ahj.2018.03.016","article-title":"The CardiAMP heart failure trial: a randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post-myocardial infarction heart failure: trial rationale and study design","volume":"201","author":"Raval","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.carrev.2020.06.031_bb5000","doi-asserted-by":"crossref","first-page":"805","DOI":"10.4244\/EIJV7I7A127","article-title":"Tansendocardial autologous bone marrow in myocardial infarction induced heart failure, two-year follow-up in an open-label Phase I safety study (the TABMMI study)","volume":"7","author":"de la Fuente","year":"2011","journal-title":"Eurointervention"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838920304164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838920304164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:19:24Z","timestamp":1761560364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838920304164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":76,"alternative-id":["S1553838920304164"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2020.06.031","relation":{},"ISSN":["1553-8389"],"issn-type":[{"value":"1553-8389","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Safety Profile of Transendocardial Catheter Injection Systems: A Plea for Uniform Reporting","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2020.06.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}